Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 7/20 | 0.42 |
| ▸ | MC5R | P33032 | 6/20 | 0.42 |
| ▸ | MC3R | P41968 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700371 | 0.82 | CARM1 (0.42) | CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL27775729 | 0.81 | CARM1 (0.41) | CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL8423289 | 0.79 | TSHR (0.50) | CARM1PRMT6PRMT8 | |
| SCHEMBL1703710 | 0.78 | MAOA (0.42) | CARM1PRMT6PRMT8MAOASIGMAR1 | |
| Acetic Acid SCHEMBL27681175 | 0.77 | REN (0.48) | CARM1PRMT6PRMT8SIGMAR1 | |
| Acetic Acid SCHEMBL4347586 | 0.76 | REN (0.47) | CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL2659990 | 0.76 | TSHR (0.48) | BCHE | |
| SCHEMBL4369012 | 0.76 | BCHE (0.58) | ACHEBCHE | |
| SCHEMBL23867189 | 0.76 | SMN1; SMN2 (0.41) | CARM1PRMT6PRMT8 | |
| SCHEMBL1704003 | 0.76 | MAOB (0.67) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2440527-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | Topo Target A/S (DK) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | CARM1 2549/4885PRMT6 699/4885PRMT8 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.